File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: High titer and avidity of nonneutralizing antibodies against influenza vaccine antigen are associated with severe influenza

TitleHigh titer and avidity of nonneutralizing antibodies against influenza vaccine antigen are associated with severe influenza
Authors
Issue Date2012
PublisherAmerican Society for Microbiology. The Journal's web site is located at http://cdli.asm.org/
Citation
Clinical And Vaccine Immunology, 2012, v. 19 n. 7, p. 1012-1018 How to Cite?
AbstractThe importance of neutralizing antibody in protection against influenza virus is well established, but the role of the early antibody response during the initial stage of infection in affecting the severity of disease is unknown. The 2009 influenza pandemic provided a unique opportunity for study because most patients lacked preexisting neutralizing antibody. In this study, we compared the antibody responses of 52 patients with severe or mild disease, using sera collected at admission. A microneutralization (MN) assay was used to detect neutralizing antibody. We also developed an enzyme-linked immunosorbent assay (ELISA) which detects both neutralizing and nonneutralizing antibodies against viral antigens from a split-virion inactivated monovalent influenza virus vaccine. While the MN titers were not significantly different between the two groups (P = 0.764), the ELISA titer and ELISA/MN titer ratio were significantly higher for patients with severe disease than for those with mild disease (P = 0.004 and P = 0.011, respectively). This finding suggested that in patients with severe disease, a larger proportion of serum antibodies were antibodies with no detectable neutralizing activity. The antibody avidity was also significantly higher in patients with severe disease than in those with mild disease (P < 0.05). Among patients with severe disease, those who required positive pressure ventilation (PPV) had significantly higher ELISA titers than those who did not require PPV (P < 0.05). Multivariate analysis showed that the ELISA titer and antibody avidity were independently associated with severe disease. Higher titers of nonneutralizing antibody with higher avidity at the early stage of influenza virus infection may be associated with worse clinical severity and poorer outcomes. Copyright © 2012, American Society for Microbiology. All Rights Reserved.
Persistent Identifierhttp://hdl.handle.net/10722/163507
ISSN
2014 Impact Factor: 2.470
2013 SCImago Journal Rankings: 1.241
PubMed Central ID
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorTo, KKWen_HK
dc.contributor.authorZhang, AJXen_HK
dc.contributor.authorHung, IFNen_HK
dc.contributor.authorXu, Ten_HK
dc.contributor.authorIp, WCTen_HK
dc.contributor.authorWong, RTYen_HK
dc.contributor.authorNg, JCKen_HK
dc.contributor.authorChan, JFWen_HK
dc.contributor.authorChan, KHen_HK
dc.contributor.authorYuen, KYen_HK
dc.date.accessioned2012-09-05T05:32:44Z-
dc.date.available2012-09-05T05:32:44Z-
dc.date.issued2012en_HK
dc.identifier.citationClinical And Vaccine Immunology, 2012, v. 19 n. 7, p. 1012-1018en_HK
dc.identifier.issn1556-6811en_HK
dc.identifier.urihttp://hdl.handle.net/10722/163507-
dc.description.abstractThe importance of neutralizing antibody in protection against influenza virus is well established, but the role of the early antibody response during the initial stage of infection in affecting the severity of disease is unknown. The 2009 influenza pandemic provided a unique opportunity for study because most patients lacked preexisting neutralizing antibody. In this study, we compared the antibody responses of 52 patients with severe or mild disease, using sera collected at admission. A microneutralization (MN) assay was used to detect neutralizing antibody. We also developed an enzyme-linked immunosorbent assay (ELISA) which detects both neutralizing and nonneutralizing antibodies against viral antigens from a split-virion inactivated monovalent influenza virus vaccine. While the MN titers were not significantly different between the two groups (P = 0.764), the ELISA titer and ELISA/MN titer ratio were significantly higher for patients with severe disease than for those with mild disease (P = 0.004 and P = 0.011, respectively). This finding suggested that in patients with severe disease, a larger proportion of serum antibodies were antibodies with no detectable neutralizing activity. The antibody avidity was also significantly higher in patients with severe disease than in those with mild disease (P < 0.05). Among patients with severe disease, those who required positive pressure ventilation (PPV) had significantly higher ELISA titers than those who did not require PPV (P < 0.05). Multivariate analysis showed that the ELISA titer and antibody avidity were independently associated with severe disease. Higher titers of nonneutralizing antibody with higher avidity at the early stage of influenza virus infection may be associated with worse clinical severity and poorer outcomes. Copyright © 2012, American Society for Microbiology. All Rights Reserved.en_HK
dc.languageengen_US
dc.publisherAmerican Society for Microbiology. The Journal's web site is located at http://cdli.asm.org/en_HK
dc.relation.ispartofClinical and Vaccine Immunologyen_HK
dc.rightsClinical and Vaccine Immunology. Copyright © American Society for Microbiology.-
dc.rightsCopyright © American Society for Microbiology, [Clinical and Vaccine Immunology, 2012, v. 19 n. 7, p. 1012-1018]-
dc.subject.meshAntibodies, Neutralizing - blood-
dc.subject.meshAntibodies, Viral - blood-
dc.subject.meshAntibody Affinity-
dc.subject.meshInfluenza A Virus, H1N1 Subtype - immunology-
dc.subject.meshInfluenza, Human - immunology - pathology - virology-
dc.titleHigh titer and avidity of nonneutralizing antibodies against influenza vaccine antigen are associated with severe influenzaen_HK
dc.typeArticleen_HK
dc.identifier.emailTo, KKW: kelvinto@hkucc.hku.hken_HK
dc.identifier.emailHung, IFN: ivanhung@hkucc.hku.hken_HK
dc.identifier.emailChan, JFW: jfwchan@hku.hken_HK
dc.identifier.emailYuen, KY: kyyuen@hkucc.hku.hken_HK
dc.identifier.authorityTo, KKW=rp01384en_HK
dc.identifier.authorityHung, IFN=rp00508en_HK
dc.identifier.authorityChan, JFW=rp01736en_HK
dc.identifier.authorityYuen, KY=rp00366en_HK
dc.description.naturelink_to_OA_fulltexten_US
dc.identifier.doi10.1128/CVI.00081-12en_HK
dc.identifier.pmid22573737en_HK
dc.identifier.pmcidPMC3393364-
dc.identifier.scopuseid_2-s2.0-84863558273en_HK
dc.identifier.hkuros203192-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-84863558273&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume19en_HK
dc.identifier.issue7en_HK
dc.identifier.spage1012en_HK
dc.identifier.epage1018en_HK
dc.identifier.isiWOS:000307110700005-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridTo, KKW=14323807300en_HK
dc.identifier.scopusauthoridZhang, AJX=37008823400en_HK
dc.identifier.scopusauthoridHung, IFN=7006103457en_HK
dc.identifier.scopusauthoridXu, T=55301280900en_HK
dc.identifier.scopusauthoridIp, WCT=55301120200en_HK
dc.identifier.scopusauthoridWong, RTY=55301241400en_HK
dc.identifier.scopusauthoridNg, JCK=55301225600en_HK
dc.identifier.scopusauthoridChan, JFW=24278817900en_HK
dc.identifier.scopusauthoridChan, KH=7406034307en_HK
dc.identifier.scopusauthoridYuen, KY=36078079100en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats